Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.

ABSTRACT:

Background

Ibrutinib is a Bruton tyrosine kinase inhibitor and is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) in frontline and relapsed/refractory settings. The authors previously reported poor outcomes for patients who discontinued ibrutinib; however, long-term outcomes were not reported.

Methods

Data from 320 patients who received ibrutinib on clinical studies between 2010 and 2015 at The University of Texas MD Anderson Cancer Center were retrospectively analyzed.

Results

Long-term outcomes among patients with CLL after they discontinued ibrutinib were analyzed. Ninety of 320 patients (28%) who were treated on ibrutinib-based regimens discontinued ibrutinib. Of these, 80 had relapsed/refractory disease, and 10 were treatment-naive.

SUBMITTER: Jain P 

PROVIDER: S-EPMC5980235 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature